Albany, NY -- (SBWIRE) -- 07/12/2017 -- HIV-associated lipodystrophy is associated with HIV infection or due to side effects of drugs used for HIV infection. The HIV-associated lipodystrophy clusters different clinical conditions, which are lipoaccumulation and lipoatrophy. While lipoaccumulation is associated with increase in visceral fat, lipoatrophy is related to subcutaneous fat loss.

The global market for HIV-associated lipodystrophy is displaying unprecedented dynamics. Firstly, the increasing research studies that are aimed at discovering the link between two mechanisms of lipodystrophy so as to enable single mechanism for fat redistribution. Across the world, improving healthcare infrastructure and rising prevalence of HIV/AIDS are fuelling the growth of the HIV-associated lipodystrophy market. However, factors such as low adoption of therapeutics and demand from patients for constant nutritional supply are restraining the market's growth.

Read Report - http://www.transparencymarketresearch.com/hiv-associated-lipodystrophy-market.html

The global market for HIV-associated lipodystrophy can be segmented on the basis of therapeutic class, distribution channel, lipodystrophy type, and geography. In terms of lipodystrophy type, the market can be segmented into lipoatrophy and lipoaccumulation. By therapeutic class, the market can be segmented into anabolism modulators, mitochondrial antioxidants, insulin resistance modulators, and miscellaneous metabolic agents. The segment of anabolism modulators can be further sub-segmented into thiazolididiones, metformins, and others.

In terms of distribution channel, the market can be categorized into hospital pharmacy stores, online pharmacies, and retail pharmacy stores. Among these, hospital pharmacy stores are expected to hold the leading share as they are easy to connect to and trend of use of advanced products among end-users.

In terms of geography, the global HIV-associated lipodystrophy market can be segmented into: Asia Pacific, North America, Europe, the Middle East and Africa, and Latin America. Amongst these, Asia Pacific is expected to display the leading growth rate due to an increasing patient pool, rising demand for low cost therapeutics, rising awareness about the treatment for HIV-associated lipodystrophy, and increasing spending on modern healthcare.

However, North America is expected to be the leading regional market for HIV-associated lipodystrophy owing to an increasing adoption of technology-driven medical care, high per capita expenditure on healthcare, and significant investments for research and development of effective treatments.

The top players in the global HIV-associated Lipodystrophy market include Novelion Therapeutics Inc., Gilead Sciences Inc., AbbVie Inc., AstraZeneca plc, Theratechnologies Inc., GlaxoSmithKline plc, and Bristol-Myers Squibb Company.

Download a PDF Brochure of Report - http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22925"